Equity Field Notes from temporal sources

[DanWebzster]

CTIC raised $55.8mn in 2/18 and now has a cash runway thru 2019

developing a compound for those ineligible for Ruxolitinib. CELG also has interest in the area, have recently acquired a similar compound

FDA clinical hold has been lifted by moving forward with a lower dose. During the clinical hold, FDA allowed compassionate use of
the compound

In 3Q18, MAA will decide on marketing approval.

1Q19, MAA will read out Ph3.